LY3410738: a first-in-class covalent inhibitor of mutant IDH1 in CCA

preview_player
Показать описание
Rachna T. Shroff, MD, University of Arizona Cancer Center, Tucson, AZ, discusses an ongoing Phase I study evaluating LY3410738, a first-in-class covalent inhibitor of mutant IDH1 in cholangiocarcinoma (CCA) and other advanced solid tumors. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
  1. VJOncology
  2. Speaker: Rachna T. Shroff
  3. Institution: University of Arizona Cancer Center
  4. Event: VJVirtual
  5. Event: ASCO GI 2021
  6. Format: Interview
Рекомендации по теме
LY3410738: a first-in-class 0:01:52

LY3410738: a first-in-class covalent inhibitor of mutant IDH1 in CCA

Phase I study 0:01:35

Phase I study of LY3410738: a first-in-class IDH1-R132 inhibitor

Non-covalent vs covalent 0:02:23

Non-covalent vs covalent BTK inhibitors in CLL

Targeted covalent inhibitors 0:42:00

Targeted covalent inhibitors with an emphasis on reversible covalent inhibition

Design and synthesis 1:09:17

Design and synthesis of covalent allosteric probes

Comparing BTK and 0:05:00

Comparing BTK and BCL-2 inhibitor outcomes in different CLL subgroups

BAY1436032: IDH1 inhibition 0:03:01

BAY1436032: IDH1 inhibition in IDH1-mutated AML

Machine Learning Models 0:56:00

Machine Learning Models for Proteome-wide Covalent Drug Design

ICRN/ENS-CCA Translational Science 0:57:28

ICRN/ENS-CCA Translational Science Webinar Series: 'Next Steps with FGFRi”

FGFR Inhibitor Toxicity 0:06:00

FGFR Inhibitor Toxicity Profile

2021 NSofT Symposium: 0:29:47

2021 NSofT Symposium: Nir London, PhD

Dr. Rachna Shroff 0:00:46

Dr. Rachna Shroff On Why You Should Attend ASCO #GI23

Discover How She 0:01:55

Discover How She Became a 25-Year Brain Tumor Survivor

Impressive response to 0:03:56

Impressive response to dual BRAF + MEK inhibition in 2 patients with BRAF mutant cholangiocarcinoma

Neoadjuvant targeted therapy 0:02:40

Neoadjuvant targeted therapy in BRAF V600 mutated melanoma

Webinar: HER2-targeted therapies 0:59:44

Webinar: HER2-targeted therapies in CCA

UArizona Cancer Center 0:02:44

UArizona Cancer Center GI Clinical Research Team: Colorectal Cancer Awareness

Dr. Shroff on 0:01:25

Dr. Shroff on Genomic Landscape of Cholangiocarcinoma

Bile Duct Cancer 0:00:47

Bile Duct Cancer | Symptoms & Treatment

Rachna Shroff, MD, 0:03:18

Rachna Shroff, MD, shares perspective on newly approved targeted therapies in hepatobiliary cancer

Rachna Shroff, MD, 0:03:30

Rachna Shroff, MD, on the most promising pathways for targeted therapies in GI cancers

AC21 - Rachna 0:15:17

AC21 - Rachna Shroff: Closing the GAP

Rachna Shroff, MD, 0:00:47

Rachna Shroff, MD, discusses how BRAF mutations figure into cholangiocarcinoma treatment

AC20 - Welcome 0:02:34

AC20 - Welcome Day 3